Aroa Biosurgery

Focus: Aroa Biosurgery is a New Zealand-based biotech focused on soft-tissue regeneration products for dermatology and wound care applications. The company operates as a specialized player in the medical device/regenerative medicine space with a modest pipeline of marketed and development-stage products.

Dermatology

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Open Jobs

5+1 this month

Stable — net +1 jobs in 30d

5 added, 4 removed. Backfill posture.

Should You Work at Aroa Biosurgery?

AI assessment

Aroa is a high-risk, high-upside early-stage play suitable for operators seeking commercialization experience in regenerative medicine, but only if risk tolerance is high and financial due diligence is completed independently.

Why Work Here

Early-stage biotech with commercial momentum—Myriad Matrix is in Phase 4 (post-market), indicating revenue-generating potential and moving beyond pure R&D phase

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Myriad Matrix

Soft Tissue Defects

Growth

Lead commercial product in Phase 4 (post-market stage) with 2 active trials, representing the company's primary revenue engine.

Symphony

Diabetic Foot Ulcer

Help build intelligence for Aroa Biosurgery

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline addressing high-prevalence conditions: diabetic foot ulcers and chronic foot ulcers represent large unmet needs in wound care

Commercial hiring is active (2 roles) alongside supply chain roles, suggesting transition from pure development to commercialization—ground-floor opportunity for building functions

Watch Out For

Minimal public visibility: no published research output (0 publications on record), no FDA warning tracking, and no disclosed financials create visibility and stability concerns
Very small hiring footprint (4 active roles total) and limited headcount data suggest early-stage constraints; geographic isolation in Auckland may limit network and exit opportunities
Unclear financial runway: no disclosed funding, revenue, or cash position—career stability cannot be assessed

Generated by Claude from Aroa Biosurgery's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Development-stage product addressing a large, high-prevalence chronic disease indication with 2 active trials.

Endoform

Chronic Foot Ulcer

Growth

Early-stage program with no active trials; represents future pipeline optionality in the foot ulcer market.

Pipeline & Clinical Trials

Endoform

Chronic Foot Ulcer

N/A

Clinical Trials (1)

NCT06035523Clinical Study Evaluating Wound Closure With Endoform™ and Symphony™

N/A

Symphony

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT06035536Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers

N/A

Myriad™ applied in conjunction with NPWT

Soft Tissue Defects

Phase 4

Clinical Trials (1)

NCT07385313Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures

Phase 4

Myriad Matrix

Soft Tissue Defects

Phase 4

Clinical Trials (1)

NCT05243966Myriad™ Augmented Soft Tissue Reconstruction Registry

N/A

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Dermatology

Open Roles: 5 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Dermatology

2 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Aroa Biosurgery

Should You Work at Aroa Biosurgery?

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Open Jobs (5)

Senior Design Quality Engineer

Process Development Engineer

Business Analyst

Distributor Network Manager - East

Expressions of Interest - work with AROA

Hiring Trend